The NUCALA patient

NUCALA may help your patients 6 years and older with severe asthma and:

Inhaler icon

High-dose ICS* plus additional controller

Lung icon

2+ exacerbations in the previous 12 months and/or daily OCS

Blood eosinophils icon

Baseline blood eosinophils ≥ 150 cells/μL, which is predictive of efficacy for NUCALA

PATIENT PROFILE

Severe eosinophilic asthma with frequent exacerbations

Male with severe eosinophilic asthma with frequent exacerbations
Male with severe eosinophilic asthma with frequent exacerbations

Reason for visit:

Follow-up after OCS burst for asthma exacerbation due to the common cold

 

Complaints:

  • Frequent asthma symptoms waking her up late at night/early morning
  • 2 visits to the ED/urgent care requiring OCS bursts for nocturnal asthma attacks that did not improve with rescue inhaler
  • Increased use of rescue inhaler
  • Symptoms limiting exercise and social activity

Medical history:

  • Asthma duration: 25 years
  • Atopic status: positive (prior SCIT)
  • Allergic rhinitis

Current asthma medications:

  • High-dose ICS/LABA (15 years)
  • Albuterol as needed (currently averaging 6 puffs/day)

Spirometry results:

  • FEV1 58% predicted
  • FEV1/FVC ratio: 0.67

Laboratory results:

  • Eosinophil count: 275 cells/μL
  • IgE concentration: 130 kU/L


From an expert: frequent exacerbations

See how NUCALA can help SEA patients with frequent exacerbations.

PATIENT PROFILE

Severe eosinophilic asthma with OCS dependence

Female with severe eosinophilic asthma OCS dependent
Female with severe eosinophilic asthma OCS dependent

Reason for visit:

Follow-up after ED visit 2 weeks prior for asthma exacerbation due to lower respiratory tract infection

 

Complaints:

  • Asthma symptoms interfering with work and limiting exercise
  • Expressed concern about long-term side effects of OCS
  • Weight gain of 10 pounds in the last year (BMI, 27.5 kg/m2)

Medical history:

  • Asthma duration: 15 years
  • Intermittent OCS bursts for 6 months with a subsequent switch to OCS maintenance therapy
  • Since start of OCS maintenance therapy, patient has had 2 exacerbations requiring bursts of OCS

Current asthma medications:

  • High-dose ICS/LABA (10 years) + LAMA (5 years)
  • OCS 10 mg/day
  • Albuterol as needed

Spirometry results:

  • FEV1 55% predicted
  • FEV1/FVC ratio: 0.64

Laboratory results:

  • Eosinophil count: 180 cells/μL
  • IgE concentration: 117 kU/L


From an expert: SEA with OCS dependence

See how NUCALA can help OCS-dependent patients.

PATIENT PROFILE

Severe eosinophilic asthma with comorbid nasal polyps

Male with severe eosinophilic asthma comorbid nasal polyps
Male with severe eosinophilic asthma comorbid nasal polyps

Reason for visit:

Routine checkup

 

Complaints:

  • Persistent dyspnea that disrupts sleep

Medical history:

  • Asthma duration: 20 years
  • 2 exacerbations in the past year, with 1 leading to hospitalization
  • Presence of nasal polyps
  • Atopic status: positive (prior SCIT)

Current asthma medications:

  • High-dose ICS/LABA (13 years) + LTRA (6 years)
  • Albuterol as needed

Spirometry results:

  • FEV1 66% predicted
  • FEV1/FVC ratio: 0.69

Laboratory results:

  • Eosinophil count: 324 cells/μL
  • IgE concentration: 352 kU/L


From an expert: exacerbations with comorbid nasal poylps

See how NUCALA can help SEA patients with frequent exacerbations and comorbid nasal polyps.

PATIENT PROFILE

Severe eosinophilic asthma with allergic characteristics

Male with severe eosinophilic asthma comorbid nasal polyps
Male with severe eosinophilic asthma comorbid nasal polyps

Reason for visit:

Routine office visit

 

Complaints:

  • Persistent dyspnea, cough, and intermittent wheezing
  • Asthma symptoms have forced her to miss work and cancel family plans

Medical history:

  • Asthma duration: 22 years
  • Atopic status: positive (prior SCIT)
  • Allergic rhinosinusitis
  • 2 exacerbations in the past year (outpatient treated with OCS burst)

Current asthma medications:

  • High-dose ICS/LABA (10 years)
  • Albuterol as needed (~4x weekly)

Spirometry results:

  • FEV1 66% predicted
  • FEV1/FVC ratio: 0.70

Laboratory results:

  • Eosinophil count: 330 cells/μL
  • IgE concentration: 315 kU/L

Pediatric Use (ages 6-11)

NUCALA is approved for patients with severe eosinophilic asthma down to age 6.

NUCALA may help your patients aged 6 to 11 years with severe asthma, and:

Inhaler icon

Medium- to high-dose ICS* plus additional controller

Lung icon

2+ exacerbations in the previous 12 months

Blood eosinophils icon

Baseline blood eosinophils ≥150 cells/μL, which is predictive of efficacy for NUCALA

*Medium- to high-dose ICS defined as >200 µg/day fluticasone propionate dry powder inhaler or equivalent daily.1

Defined as worsening of asthma requiring: systemic corticosteroids or hospitalization or ED visit; or at least double the existing maintenance systemic corticosteroid dose for ≥3 days.

PATIENT PROFILE

Severe eosinophilic asthma in pediatric patients

Young female with severe eosinophilic asthma
Young female with severe eosinophilic asthma

Reason for visit:

Mother called nurse with concern about current symptoms

 

Complaints:

  • Intermittent wheezing and dyspnea
  • Frequent use of rescue inhaler
  • Missed school due to asthma symptoms

Medical history:

  • Asthma duration: 4 years (diagnosed at age 6)
  • 2 exacerbations in the past year, including a hospitalization
  • Atopic status: positive (prior SCIT)

Current asthma medications:

  • High-dose ICS/LABA (3 years)
  • Albuterol as needed (currently averaging 4 puffs/day)

Spirometry results:

  • FEV1 68% predicted
  • FEV1/FVC ratio: 0.73

Laboratory results:

  • Eosinophil count: 370 cells/μL
  • IgE concentration: 148 kU/L

BMI=body mass index; ED=emergency department; FEV1=forced expiratory volume in 1 second; FVC=forced vital capacity; ICS=inhaled corticosteroid; IgE=immunoglobulin E; LABA=long-acting beta2-agonist; LAMA=long-acting muscarinic antagonist; LTRA=leukotriene receptor antagonist; OCS=oral corticosteroid; SCIT=subcutaneous immunotherapy; SEA=severe eosinophilic asthma.